Needham & Company LLC reiterated their buy rating on shares of Stoke Therapeutics (NASDAQ:STOK - Free Report) in a research report report published on Tuesday,Benzinga reports. The brokerage currently has a $22.00 price target on the stock.
A number of other research firms have also recently commented on STOK. Cantor Fitzgerald upgraded shares of Stoke Therapeutics to a "strong-buy" rating in a research note on Wednesday, May 14th. Chardan Capital reaffirmed a "buy" rating and issued a $24.00 price target on shares of Stoke Therapeutics in a report on Wednesday, March 19th. Finally, HC Wainwright lowered their price objective on shares of Stoke Therapeutics from $47.00 to $35.00 and set a "buy" rating for the company in a research note on Wednesday, May 14th. Five equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, Stoke Therapeutics presently has an average rating of "Buy" and an average price target of $23.20.
View Our Latest Analysis on Stoke Therapeutics
Stoke Therapeutics Price Performance
NASDAQ STOK traded down $0.07 during trading on Tuesday, hitting $11.49. The company's stock had a trading volume of 185,804 shares, compared to its average volume of 672,441. Stoke Therapeutics has a fifty-two week low of $5.35 and a fifty-two week high of $16.15. The company has a market cap of $627.08 million, a PE ratio of 14.54 and a beta of 1.14. The business's 50 day simple moving average is $10.43 and its 200-day simple moving average is $9.57.
Insiders Place Their Bets
In other Stoke Therapeutics news, insider Barry Ticho sold 6,471 shares of the firm's stock in a transaction that occurred on Tuesday, June 3rd. The shares were sold at an average price of $10.03, for a total transaction of $64,904.13. Following the completion of the transaction, the insider directly owned 25,782 shares of the company's stock, valued at approximately $258,593.46. This trade represents a 20.06% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 9.50% of the company's stock.
Institutional Trading of Stoke Therapeutics
Hedge funds and other institutional investors have recently made changes to their positions in the business. Rhumbline Advisers lifted its holdings in shares of Stoke Therapeutics by 6.0% in the 4th quarter. Rhumbline Advisers now owns 49,374 shares of the company's stock valued at $545,000 after buying an additional 2,787 shares during the period. Bank of New York Mellon Corp raised its position in Stoke Therapeutics by 1.4% during the fourth quarter. Bank of New York Mellon Corp now owns 93,195 shares of the company's stock valued at $1,028,000 after acquiring an additional 1,330 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in Stoke Therapeutics by 8.2% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 342,129 shares of the company's stock valued at $3,774,000 after acquiring an additional 25,995 shares during the period. Swiss National Bank lifted its holdings in Stoke Therapeutics by 20.4% in the fourth quarter. Swiss National Bank now owns 67,300 shares of the company's stock valued at $742,000 after acquiring an additional 11,400 shares during the period. Finally, Teacher Retirement System of Texas purchased a new stake in Stoke Therapeutics in the 4th quarter worth approximately $113,000.
Stoke Therapeutics Company Profile
(
Get Free Report)
Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.
Recommended Stories
Before you consider Stoke Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Stoke Therapeutics wasn't on the list.
While Stoke Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
